Dublin, Dec. 06, 2022 (GLOBE NEWSWIRE) -- The "Global mRNA Therapeutics Market Size, Share & Trends Analysis Report by Application (Infectious Diseases, Oncology), by Type (Prophylactic Vaccines, Therapeutic Drugs), by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global mRNA therapeutics market size is expected to reach USD 37.76 billion by 2030. It is expected to expand at a CAGR of 1.7% from 2022 to 2030.
One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs. The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.
Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications.
These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favorable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.
For instance, in March 2022, The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.
As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology.
For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.
|No. of Pages||150|
|Forecast Period||2022 - 2030|
|Estimated Market Value (USD) in 2022||$33.02 Billion|
|Forecasted Market Value (USD) by 2030||$37.76 Billion|
|Compound Annual Growth Rate||1.7%|
mRNA Therapeutics Market Report Highlights
- By application, the infectious diseases segment held a dominant share in 2021 owing to the increased patient population and awareness regarding infectious diseases
- By type, the prophylactic vaccines segment led the market in 2021. One of the key factors propelling the growth of the prophylactic vaccines business is the rising demand for prophylactic vaccinations, particularly the new COVID-19 vaccines
- By end-use, the hospitals and clinics segment captured the largest revenue share in 2021. The segment is being driven by the increasing number of patients visiting hospitals and clinics
- North America held the largest revenue share in 2021 owing to an increase in demand for COVID-19 mRNA vaccines, the existence of major players operating in the U.S., the availability of a technologically advanced healthcare research framework, and the presence of high R&D investment
- Europe is expected to grow significantly during the forecast period due to the rising occurrence of new diseases, which has prompted efforts for immunization against specific infectious diseases like COVID 19
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Market Definitions
Chapter 3 Executive Summary
Chapter 4 Global mRNA Therapeutics Market Variables, Trends, & Scope
4.1 mRNA Therapeutics Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration and Growth Prospect Mapping
4.3 Regulatory Framework
4.4 Market Driver Analysis
4.4.1 Rise In Prevalence Of Cancer
4.4.2 Academic And Industrial Interest In mRNA
4.4.3 Advantages Of mRNA Vaccines
4.4.4 Growing Demand For Therapeutic Medicines
4.4.5 Outbreak of Covid-19
4.5 Market Restraint Analysis
4.5.1 Stringent Government Regulations For mRNA-Based Product Approvals
4.6 Porter's Five Forces Analysis
4.7 Pipeline Analysis
Chapter 5 mRNA Therapeutics - Segment Analysis, by Application, 2020 - 2030 (USD Million)
Chapter 6 mRNA Therapeutic Market- Segment Analysis, By Type, 2020 - 2030 (USD Million)
Chapter 7 mRNA Therapeutic Market- Segment Analysis, By End-Use, 2020 - 2030 (USD Million)
Chapter 8 mRNA Therapeutic Market: - Segment Analysis, By Region, 2020 - 2030 (USD Million)
Chapter 9 Competitive Landscape
9.1 Public Companies
9.1.1 Company Market Position Analysis
9.1.2 Competitive Dashboard Analysis
9.1.3 Strategic Framework
9.2 Private Companies
9.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
9.2.2 Regional Network Map
9.3 Company Profiles
9.3.1 MODERNA, INC.
220.127.116.11 Company Overview
18.104.22.168 Alere, Inc.
22.214.171.124 Financial Performance
126.96.36.199 Product Benchmarking
188.8.131.52 Strategic Initiatives
9.3.2 BIONTECH SE
184.108.40.206 Company Overview
220.127.116.11 Financial Performance
18.104.22.168 Product Benchmarking
22.214.171.124 Strategic Initiatives
9.3.3 CUREVAC N.V.
126.96.36.199 Company Overview
188.8.131.52 Financial Performance
184.108.40.206 Product Benchmarking
220.127.116.11 Strategic Initiatives
9.3.4 ARCTURUS THERAPEUTICS
18.104.22.168 Company Overview
22.214.171.124 Financial Performance
126.96.36.199 Product Benchmarking
188.8.131.52 Strategic Initiatives
9.3.5 TRANSLATE BIO, INC.
184.108.40.206 Company Overview
220.127.116.11 Financial Performance
18.104.22.168 Product Benchmarking
22.214.171.124 Strategic Initiatives
9.3.6 GSK PLC.
126.96.36.199 Company Overview
188.8.131.52 Financial Performance
184.108.40.206 Product Benchmarking
220.127.116.11 Strategic Initiatives
9.3.7 ARGOS THERAPEUTICS INC.
18.104.22.168 Company Overview
22.214.171.124 Financial Performance
126.96.36.199 Product Benchmarking
188.8.131.52 Strategic Initiatives
9.3.8 SANGAMO THERAPEUTICS, INC.
184.108.40.206 Company Overview
220.127.116.11 Financial Performance
18.104.22.168 Product Benchmarking
22.214.171.124 Strategic Initiatives
9.3.9 PFIZER INC.
126.96.36.199 Company Overview
188.8.131.52 Financial Performance
184.108.40.206 Product Benchmarking
220.127.116.11 Strategic Initiatives
9.3.10 ASTRAZENECA PLC.
18.104.22.168 Company Overview
22.214.171.124 Financial Performance
126.96.36.199 Product Benchmarking
188.8.131.52 Strategic Initiatives
9.3.11 CRISPR THERAPEUTICS AG
184.108.40.206 Company Overview
220.127.116.11 Financial Performance
18.104.22.168 Product Benchmarking
22.214.171.124 Strategic Initiatives
For more information about this report visit https://www.researchandmarkets.com/r/ikocii
CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900